Cryoport, Inc.

Cryoport, Inc. provides temperature-controlled supply chain solutions primarily for the biopharmaceutical, pharmaceutical, animal health, and reproductive medicine markets globally. The company operates through two main segments: Life Sciences Services and Life Sciences Products. Its Life Sciences Services segment offers temperature-controlled logistics, biostorage, bioservices, and cryopreservation services. The Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars, and related accessories. Key products include Cryoport Express Shippers, Cryoport Elite, Cryoport Express Cryogenic HV3 Shipping System, Smartpak Condition Monitoring System, and Tec4Med IoT-based monitoring solutions. The company also offers IntegriCell services for apheresis/leukapheresis collection, cryoshuttle transportation, and cryopreservation, as well as consulting services and MVE Fusion and Vario cryogenic systems.

Cryoport, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CYRX. The company's financials are reported in US Dollars (USD), as it is based in the United States. Being listed on NasdaqCM provides the company with access to a major US stock exchange, which is known for hosting many technology and growth-oriented companies. Investors trading CYRX shares typically do so in USD, and the stock is subject to the regulatory framework of the US Securities and Exchange Commission (SEC).

Cryoport, Inc. operates in the Industrials sector and is classified under the Integrated Freight & Logistics industry. This classification reflects the company's core business of providing specialized logistics and supply chain solutions, particularly for temperature-sensitive products in the life sciences field. As an integrated freight and logistics company, Cryoport manages the transportation, storage, and handling of critical biological materials, such as cell and gene therapies, vaccines, and reproductive medicine specimens. The company's services are essential for maintaining the integrity of these products throughout the supply chain, from collection to delivery.

Cryoport, Inc. serves the biopharmaceutical, pharmaceutical, animal health, and reproductive medicine markets globally. The company's temperature-controlled supply chain solutions are used by clients worldwide, including in the United States, Europe, and other regions. Cryoport's services support the transport and storage of sensitive biological materials such as cell and gene therapies, vaccines, semen, embryos, and other specimens. The company's global reach is facilitated by its network of logistics hubs and partnerships, enabling it to provide end-to-end solutions for clinical trials, commercial distribution, and reproductive medicine applications. Cryoport's international presence allows it to serve customers in various countries, ensuring compliance with local regulations and maintaining product quality across borders.

Cryoport offers a comprehensive portfolio of products and services for temperature-controlled supply chain management. Key products include Cryoport Express Shippers, Cryoport Elite, Cryoport Express Cryogenic HV3 Shipping System, Smartpak Condition Monitoring System, and Tec4Med IoT-based monitoring solutions. The company also provides cryogenic freezers and dewars under the MVE brand, such as the MVE Fusion and MVE Vario systems. On the services side, Cryoport's Life Sciences Services segment includes temperature-controlled logistics, biostorage, bioservices, and cryopreservation. Specific services include controlled temperature storage, kitting, labeling, fulfillment, sample management, drug return, and Qualified Person drug product release. Additionally, IntegriCell services cover apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation. Cryoport also offers consulting services and archiving, monitoring, tracking, receipt, and delivery of samples and frozen biological specimens.